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Abstract
Alcohol Use Disorder (AUD) is a significant health problem that is seen widely in
all hospitals and in the community. Individuals who have AUD and cease to consume
alcohol develop Alcohol Withdrawal Syndrome (AWS). Alcohol Withdrawal Syndrome
can either be treated on an inpatient or outpatient basis. Three different pharmacological
regimens for treating AWS with medications exist. The three regimens include fixeddosing, symptom-triggered, and loading dose regimens (Sachdeva et al., 2015). As Acute
Care Nurse Practitioners (APRNs), AWS will be a common diagnosis treated. Advanced
Practice Registered Nurses (APRNs) must be aware of the different treatment modalities
and the best evidence-based regimens for treating AWS. The purpose of this project is to
conduct a systematic review to determine if the use of symptom-triggered dosing
compared to fixed-schedule dosing of benzodiazepines for the treatment of AWS
decreases total dosage of benzodiazepines administered during the course of treatment.
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Symptom Triggered Therapy Versus Fixed-Dosed Scheduling for Alcohol Withdrawal: A
Systematic Review
Background/Statement of the Problem
Alcohol Use Disorder (AUD) is a significant health problem that is seen widely in
all hospitals and in the community. Alcohol Use Disorder is defined as “a chronic
relapsing brain disease characterized by compulsive alcohol use, loss of control over
alcohol intake, and a negative emotional state when not using” (National Institute on
Alcohol Abuse and Alcoholism [NIAAA], 2019). The over consumption of alcohol can
also be associated with other comorbidities making it difficult to treat. According to the
NIAAA, about 16 million Americans over the age of 18 have AUD, an increase from 15
million in 2015.
Individuals who have AUD and cease to consume alcohol develop Alcohol
Withdrawal Syndrome (AWS). Alcohol Withdrawal Syndrome is characterized by a
cluster of symptoms that can range from mild to severe from the cessation or reduction in
excessive alcohol consumption (Sachdeva et al., 2015). Proper treatment with
medications is indicated in all cases of AWS, from mild to severe (Sachdeva et al., 2015).
The preferred pharmacological treatment method for AWS is with benzodiazepines
(Sachdeva et al., 2015). The goal of AWS treatment with benzodiazepines is to reach a
calm but awake and oriented state (Sachdeva et al., 2015). According to Sachdeva
(2015), without the prompt and adequate amount of benzodiazepine administration, AWS
can be fatal.
Alcohol Withdrawal Syndrome can either be treated on an inpatient or outpatient
basis. Patients who are at low risk of developing severe withdrawal symptoms can be
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treated as outpatients (Sachdeva et al., 2015). Patients who develop moderate or severe
AWS and have other medical-comorbidities and multiple failed attempts at staying sober
need close inpatient monitoring (Sachdeva et al., 2015). Three different pharmacological
regimens for treating AWS with medications exist. The three regimens include fixeddosing, symptom-triggered, and loading dose regimens (Sachdeva et al., 2015). With
fixed-schedule dosing (FSD), benzodiazepines are administered at scheduled times.
During FSD, benzodiazepines are tapered slowly, and they are administered regardless of
whether a patient is experiencing symptoms or not (Skinner, 2014). In symptom-triggered
therapy (STT), benzodiazepines are administered in response to the development of
withdrawal symptoms that are monitored using the Clinical Institute Withdrawal Scale
(CIWA) (Skinner, 2014). With this therapy, patients only receive medication when they
are exhibiting symptoms. Loading dose regimens (LDRs) use long-acting
benzodiazepines in large doses to reduce the risk of complications (Sachdeva et al.,
2015).
As Acute Care Nurse Practitioners (APRNs), AWS will be a common diagnosis
treated. According to Sachdeva et al. (2015), inpatient treatment of AWS results in a
higher cost for inpatient treatment of AWS. Advanced Practice Registered Nurses
(APRNs) must be aware of the different treatment modalities and the best evidence-based
regimens for treating AWS.
The purpose of this project is to conduct a systematic review to determine if the
use of symptom-triggered dosing compared to fixed-schedule dosing of benzodiazepines
for the treatment of AWS decreases total dosage of benzodiazepines administered during
the course of treatment.
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Literature Review
A literature review was conducted using the databases CINAHL and Google
Scholar. Multiple search terms including alcohol withdrawal, alcohol abuse treatment,
symptom-triggered therapy, and fixed-dosed therapy were used in the search. Only
articles in English language and with full-texts were used in the searches. Inclusion
criteria were comprised of articles that included inpatients, outpatients, and adults (ages
18 and over). Exclusion criteria included pediatrics (younger than 18 years old). Articles
from the years 2010-2020 were searched.
Alcohol Use Disorder
Alcohol Use Disorder (AUD) is a significant health problem that is seen widely in
all hospitals and in the community. Alcohol Use Disorder is defined as “a chronic
relapsing brain disease characterized by compulsive alcohol use, loss of control over
alcohol intake, and a negative emotional state when not using” (National Institute on
Alcohol Abuse and Alcoholism [NIAAA], 2019). The over consumption of alcohol can
also be associated with other comorbidities making it difficult to treat. According to the
NIAAA, about 16 million Americans over the age of 18 have AUD, an increase from 15
million in 2015. Individuals who have AUD and cease to consume alcohol develop
Alcohol Withdrawal Syndrome (AWS).
Alcohol Withdrawal Syndrome
Alcohol is a central nervous system (CNS) depressant that acts on two major
pathways, the inhibitory y-aminobutyric acid (GABA) and excitatory N-methyl-Daspartate (NMDA glutamate) pathways. Glutamate and GABA are the major
neurotransmitters in the brain. Inhibitory GABA and excitatory glutamate work together
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to maintain the brain’s overall level of excitation. GABA’s function is to decrease the
activity of the neurons to which it binds (Perry, 2014). GABA receptors are channel
receptors in the brain to which GABA binds. When GABA binds to these receptors, the
receptors change shape to allow negatively charged chloride ions to enter the neuron,
making the neuron more negative and less likely to respond to stimuli, reducing its
excitability (Perry, 2014). This property is what makes GABA an inhibitory
neurotransmitter.
Glutamate is another chemical messenger and neurotransmitter found in the brain.
When glutamate binds to an NMDA receptor, positive sodium and calcium ions flow into
the neuron, causing the neuron to be more positive and more likely to respond to stimuli,
thus being the excitatory pathway (Perry, 2014). With alcohol consumption, the activity
of GABA at the receptors increases, causing negative chloride ions to influx into the
neuron and leading to inhibitory effects (Perry, 2014). Simultaneously, alcohol
consumption blocks the excitatory action of glutamate at the NMDA receptors, causing
sedative and depressant effects (Perry, 2014). With prolonged alcohol consumption,
GABA receptors are down-regulated, and NMDA receptors are up-regulated to maintain
homeostasis (Perry, 2014). When an individual abruptly discontinues the consumption of
alcohol, an excitatory state develops because of these changes (Perry, 2014). This
excitatory state includes tremors, agitation, anxiety, restlessness, diaphoresis,
hallucinations, and headaches. This excitatory state is what causes the signs and
symptoms of alcohol withdrawal.
Alcohol Withdrawal Syndrome (AWS) is a very common diagnosis seen in acute
care facilities (Perry, 2014). Alcohol withdrawal syndrome (AWS) is diagnosed through
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a physical exam and history (Sachdeva et al., 2015). During the physical exam, the
provider would note tachycardia, hypertension, tachypnea, diaphoresis, agitation,
vomiting, and, at times, fever (Perry, 2014). Neurological symptoms of AWS include
visual/auditory/tactile hallucinations and seizures. Laboratory work is not necessary for
diagnosis, a provider may obtain a blood alcohol level (BAL) to know how much alcohol
a person has consumed. When diagnosing the syndrome, the provider must obtain a very
detailed history regarding the amount and frequency of alcohol intake the patient has
consumed (Sachdeva et al., 2015). For the diagnosis of AWS to be made, the following
conditions need to be in met: clear evidence of recent cessation or reduction of alcohol
consumption; symptoms of alcohol withdrawal cannot be due to other diagnoses; and the
symptoms of AWS must cause a decline in functional status and other important areas of
functioning such as inability to perform ADL’s, inability to ambulate with a steady gait,
and inability to concentrate (Sachdeva et al., 2015). The Diagnostic and Statistical
Manual of Mental Disorders (DSM-V) outlines the same diagnostic criteria for AWS as
Sachdeva et al. (2015) presents. The DSM-V states a cessation or reduction in alcohol
consumption must be present. For the DSM-V diagnostic criteria, patients must also
demonstrate two of the following symptoms: sweating, tachycardia, increased hand
tremor, insomnia, nausea or vomiting, visual/auditory/tactile hallucinations, and seizures
(Perry, 2014).
According to Adis Medical Writers (2014), 20% of hospitalized patients abuse
alcohol or are alcohol dependent and, of these, 8% will develop symptoms of AWS while
hospitalized. Individuals who abruptly stop drinking alcohol may develop AWS.
According to Murdoch et al. (2014), the onset of symptoms of AWS can occur after 48
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hours and up to 72 hours from the last alcoholic beverage consumed. The symptoms of
AWS include tremors, sweating, auditory hallucinations, visual hallucinations, tremors,
insomnia, nausea, vomiting, tactile disturbances, agitation, anxiety, and seizures
(Murdoch et al., 2014). Alcohol withdrawal seizures can occur within the first 48 hours
after the cessation of alcohol (Perry, 2014). Delirium tremors (DTs) are the most lifethreatening complications of AWS and occur in 5% of hospitalized patients (Perry,
2014). Delirium tremor symptoms include severe agitation, tremors, disorientation,
hallucinations, and increased tachycardia, hypertension, and tachypnea (Perry, 2014).
Delirium tremor symptoms can begin three to five days after the last drink and can persist
for up to seven days (Perry, 2014).
Morbidity and Mortality from AWS
Larson et al. (2012) report that patients who present to the hospital for alcohol
withdrawal have a high rate of readmission and experience significant morbidity and
mortality. Patients with AWS may also have comorbidities that worsen their morbidity
and mortality rates (Larson et al., 2012). Patients who have acute respiratory distress
syndrome (ARDS) or septic shock are at increased risk for complications and multiple
organ dysfunction (Larson et al., 2012). According to Larson et al. (2012), patients in the
intensive care unit (ICU) who have alcohol dependence have higher morbidity, including
septic shock, and higher hospital mortality. Larson et al. (2012) report that in-hospital
mortality from AWS is high but with benzodiazepines, hospital mortality rates have
decreased.
Cost Due to AWS
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Alcohol withdrawal syndrome contributes a high burden to social costs (Soravia
et al., 2018). Sachdeva et al. (2015) state that the choice of treatment setting has
important cost implications. Inpatient treatment of AWS leads to a higher cost compared
to outpatient treatment (Sachdeva et al., 2015). A higher cost with inpatient treatment
occurs due to the occurrence of more severe symptoms (Sachdeva et al., 2015). When an
individual experiencing AWS presents to a physician’s office or emergency department,
choice of treatment is made depending on the severity of withdrawal symptoms
(Sachdeva et al., 2015). The experience of moderate to severe withdrawal symptoms in
addition to a patient’s comorbidities increases the amount of benzodiazepines given,
which increases cost and the level of care required (Sachdeva et al., 2015).
Clinical Institute Withdrawal Assessment (CIWA)
The Clinical Institute Withdrawal Assessment for Alcohol-Revised Scale (CIWAAr) is a validated scale used to assess symptoms of alcohol withdrawal. There are a total
of 10 symptoms assessed using the CIWA-Ar scale including nausea/vomiting, tremors,
sweating, anxiety, agitation, headache, orientation, visual/auditory hallucinations, and
tactile disturbances (Eberly et al., 2016). The maximum score on the CIWA-Ar is 67.
Scores that are less than 10 indicate mild withdrawal, scores 10-18 indicates moderate to
severe withdrawal, and scores greater than 18 can indicate the patient is at risk for
complications if not treated (Perry, 2014). The CIWA-Ar is administered by a nurse,
requires patient participation, and takes about two minutes to administer (Perry, 2014).
The nurse asks the patient questions about the CIWA symptoms including any presence
of headache, anxiety, nausea, auditory/visual/tactile disturbances, and assesses the
patient’s orientation. The nurse objectively assesses whether the patient is experiencing
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vomiting, agitation, diaphoresis, and tremors. The CIWA-Ar scale is administered every
eight hours if the patient is not experiencing any symptoms (Perry, 2014). If the patient is
scoring between eight and ten, then hourly assessments should be completed (Perry,
2014).
Evidence Based Treatments
Non-Pharmacologic Management
Patients undergoing alcohol withdrawal should be in a quiet room with minimal
stimulation and low lighting (Sachdeva et al., 2015). Alcohol consumption causes
dehydration in individuals when withdrawing from alcohol; patients need to be
encouraged to drink fluids orally. If the patients cannot consume enough liquids orally,
then intravenous hydration would be considered (Sachdeva et al., 2015). While
consuming alcohol, patient’s nutritional status also declines. Balanced nutrition with
adequate amounts of vitamins including folic acid, multivitamin, and thiamine are
encouraged (Sachdeva et al., 2015).
Pharmacologic Management
Benzodiazepines are the first-line therapy for the treatment of alcohol withdrawal
(Adis Medical Writers, 2014). Long-acting and short-acting benzodiazepines are used for
treatment of AWS and both have advantages and disadvantages. Longer-acting
benzodiazepines provide a smoother withdrawal due to its longer-lasting effects (Adis
Medical Writers, 2014). Hepatic impairment and delirium in the elderly are two
complications of long-acting benzodiazepines that are disadvantages (Adis Medical
Writers, 2014). Short-acting benzodiazepines are preferred in the elderly and in
individuals with hepatic impairment (Adis Medical Writers, 2014). Benzodiazepines are
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metabolized by the liver, which can cause increased hepatic impairment in individuals
already compromised. Elderly patients have been shown to have a 50% decline in
clearance of benzodiazepines and a two-fold increase in accumulation of their
metabolites causing these patients to be at an increased risk of over-sedation with longacting benzodiazepines (Perry, 2014). Patients with hepatic impairment or liver disease, a
common co-morbidity for those with high alcohol intake, also have a two-fold increase in
metabolite accumulation (Perry, 2014). The short-acting benzodiazepines lorazepam and
oxazepam are preferred in the elderly and patients with hepatic impairment to decrease
the risk of over-sedation (Perry, 2014).
Benzodiazepines perform their pharmacologic action at the GABA receptors
(Eberly et al., 2016). The binding of the medication to the GABA receptors causes an
enhancement in the inhibitory action that is suppressed when drinking alcohol. This
causes reduced excitability of the neurons, causing a decrease in the symptoms of AWS,
most importantly a reduction in seizures and DTs (Eberly et al., 2016). The use of
benzodiazepines comes with many side effects and risks. Some side effects include
drowsiness, confusion, dizziness, blurred vision, weakness, slurred speech, lack of
coordination, difficulty breathing, and coma when used in excessive amounts (Uzon et
al., 2010). Chronic abuse of benzodiazepines, results in changes in relationships,
appearance, behavior, mood, and school or work performance (Uzon et al., 2010). Other
side effects of chronic abuse include insomnia, anxiety, anorexia, and headaches (Uzon et
al., 2010). The biggest risks associated with benzodiazepines are they can lead to physical
and psychological dependence (Uzon et al., 2010) or reliance on this substance. When the
substance is removed, withdrawal symptoms can occur (Uzon et al., 2010). Because of
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these side effects and risk of dependence, the treatment of AWS should ensure that the
lowest dose of benzodiazepines is given to treat the syndrome.
Three dosing strategies for the treatment of AWS with benzodiazepines are used
in practice. These treatment modalities include front-loading, fixed dose, and symptomtriggered benzodiazepine dosing (Adis Medical Writers, 2014). According to Eberly et al.
(2016), a lack of standardization for the treatment and monitoring of AWS is apparent.
The different treatment modalities will be described further.
Front Loading Dosing
According to Adis Medical Writers (2014), front-loading dosing, also known as
loading dose strategy, is the use of high doses of longer-acting benzodiazepines to
achieve rapid initial sedation and a self-tapering effect over time as the drug and its
metabolites are eliminated from the body. With this strategy, initial doses of very high
doses of benzodiazepines such as diazepam and chlordiazepoxide, are given, and doses
are repeated everyone to two hours until adequate sedation occurs (Adis Medical Writers,
2014). An average of three high doses are needed to achieve a level of sedation (Adis
Medical Writers, 2014). With this treatment, intensive monitoring is required to prevent
respiratory depression (Adis Medical Writers, 2014). According to Perry (2014), the
benefit to front-load dosing is that the most intensive monitoring and intensive
medication administration is in the early period of the treatment plan. Sachdeva et al.
(2015) state that the withdrawal severity and the clinical condition need to be monitored
before each dose of medication.
Fixed-Schedule Dosing
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A fixed-dose regimen requires that a set amount of the benzodiazepine be
administered at regular intervals without any regard to the patient’s symptoms Adis
Medical Writers, 2014). This strategy is helpful in patients who require medication
despite having or not having withdrawal symptoms such as those with history of
withdrawal seizures or delirium tremens (Adis Medical Writers, 2014). Perry (2014),
states that patients should still be monitored using the CIWA while receiving fixedschedule dosing and should be treated for breakthrough symptoms. According to Perry
(2014), these patients should also be monitored for symptoms of benzodiazepine toxicity.
According to Skinner (2014), fixed-schedule dosing is characterized by
benzodiazepines being administered at scheduled dosing and then slowly tapered.
Skinner (2014) states that fixed-dose scheduling may cause over-sedation and lead to
unnecessary medication administration to patients who do not require treatment.
Sachdeva et al. (2014) states that initial doses are determined by presenting symptoms
and the time of last alcohol consumption. According to Sachdeva et al. (2015), if a patient
is admitted and a CIWA-Ar scale cannot be obtained accurately due to symptoms, then
the fixed-dose scheduling should be used.
Symptom-Triggered Dosing
Adis Medical Writers (2014) states that symptom-triggered therapy is
administered depending on the presence of withdrawal symptoms assessed using the
CIWA-Ar scale. They further report that the duration of treatment with this method is
short and the amount of total medication administered is lower than with the fixed-dose
regimen. Cassidy et al. (2012) reports that symptom-triggered therapy for AWS can avoid
both the under-treatment or the overtreatment of AWS with benzodiazepines. Cassidy et

12

al. (2012) also states that this approach reduces cumulative benzodiazepine dosage and
duration of treatment in the hospital.
According to Perry (2014), in order for this method to be successful, patients must
be symptomatic and regular assessment of the patient’s symptoms with the CIWA-Ar
scale must be performed. Once the patients are stable, they can be reassessed every four
to eight hours (Perry, 2014). According to Skinner (2014), in symptom-triggered therapy,
benzodiazepines are administered in response to the development of AWS symptoms
while the provider uses the CIWA-Ar or another monitoring tool to assess symptoms.
The patients receiving this treatment only receive medications when they experience
symptoms (Skinner, 2014).
Sachdeva et al. (2015) described the symptom-triggered therapy approach as
giving scores using the CIWA-Ar at fixed schedules, but only giving medication when
the symptoms rated on the scale warrant it. According to Sachdeva et al. (2015),
symptom-triggered therapy is preferred over other methods because it results in the
administration of less medication and shorter duration of treatment. This method may
also decrease the risk of under medicating of over-medicating a patient (Sachdeva et al.,
2015). Sachdeva et al. (2015) states that this method can be effective if assessments of
patient’s symptoms are valid and accurate.
Total Dosage of Benzodiazepines: Fixed Schedule Dosing versus SymptomTriggered Therapy
Eberly et al. (2016) performed a retrospective chart review in October 2014 with
patients who received symptom-triggered therapy using the CIWA-Ar protocol. The
purpose of the study was to monitor the average daily dose and cumulative dose of
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diazepam given during the hospital stay. Charts were reviewed of patients who had
received at least one dose of diazepam during their stay. The pre-protocol group included
patients who had received both diazepam tapers and symptom-based therapy using the
CIWA-Ar. The post-protocol group included only patients who were receiving symptomtriggered therapy using the CIWA-Ar. A total of 174 patients were included in the study.
The average daily dose of benzodiazepine was higher in the pre-protocol group (12.1 mg)
compared to the average daily dose of the post-protocol group (5.2 mg) (Eberly et al.,
2016).
Taheri et al. (2014) also conducted a retrospective chart review in a tertiary care
center in Vancouver, Canada. The purpose of the study was to evaluate whether the
implementation of symptom-triggered therapy reduced the cumulative dose of
benzodiazepines administered. Thirty-three participants were in the pre-protocol group
and thirty were in the post-protocol group. The method of treatment in the pre-protocol
group was using a fixed-dose schedule only. In the post-protocol group, patients only
received symptom-triggered therapy. The median cumulative dose of benzodiazepines
decreased from 9 mg in the pre-protocol group to 3 mg in the post-protocol group (Taheri
et al., 2014).
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Theoretical Framework
The Middle-Range Theory of Unpleasant Symptoms was developed in 1995 by
researchers who were also involved in clinical practice. The theory states that all
symptoms are interrelated and share common causative factors (Lenz et al., 1997).
Because it is believed that symptoms share common causative factors, there can be one
theory that can guide research regarding an array of symptoms (Lenz et al., 1997). The
Theory of Unpleasant Symptoms proposes that since multiple symptoms occur together
in response to one single event, similar interventions may alleviate or treat these
symptoms (Lenz et al., 1997). The theory was updated since its original development.
The original version stated that unpleasant symptoms were unidirectional relationships
and not interrelated. The current version of the theory depicts that these symptoms may
be reciprocal (Lenz et al., 1997). Symptoms are of grave importance in health care, and
they are the main focus of this theory.
The theory is described as being comprised of three components: the symptoms
the individual is experiencing, the factors that influence the symptom experience, and the
consequences of the symptoms (Lenz et al., 1997). Lenz et al. (1997) proposes if multiple
symptoms occur together, they may exacerbate each other. All symptoms have common
characteristics, which include intensity, timing, level of distress perceived, and quality.
These characteristics are all separate, but related to one another (Lenz et al., 1997).
Intensity describes the severity, strength, or amount of symptom experienced by the
patient. Time characteristic includes frequency, duration, and timing of the symptom. The
distress dimension is the degree of effect it has on a person or how badly a person is
bothered by a symptom (Lenz et al., 1997).

15

There are three categories identified in the Theory of Unpleasant Symptoms for
influencing the intensity, timing, distress level, and quality of symptoms: physiological
factors, psychological factors, and situational factors as illustrated in Appendix C.
According to Lenz et al. (1997), these categories are also interrelated and may interact to
influence symptoms. Physiological factors include normal body functions, pathology,
trauma, and energy level (Lenz et al., 1997). Psychological components include mental
state, reaction to illness, and degree of uncertainty of symptoms and their meaning (Lenz
et al., 1997). Situational factors include social and physical environment, which are
comprised of employment status, marital status, social support, access to health care, diet,
and exercise (Lenz et al., 1997). These three factors are related to one another and
interact with each other in their relation to symptoms (Lenz et al., 1997). The final
component of the theory is performance, defined as the “outcome” or “effect” the
symptoms has on the individual (Lenz et al., 1997).
In summary, the Theory of Unpleasant Symptoms states that the experience of
unpleasant symptoms can change one’s physiological, psychological, and situational
status (Lenz et al., 1997). For example, the withdrawal symptoms seen in alcohol
withdrawal can affect a person’s mental state, medical well-being, and situational factors
such as housing. The theory stresses that symptoms can occur together and, when they
do, they can be in synchrony and have additive effects (Lenz et al., 1997). Withdrawal
symptoms can begin with one or two symptoms and as the individual progresses from
mild to moderate withdrawal, more symptoms occur and their synchrony causes an
additive effect, worsening their vital signs and mental state. This theory stresses the
importance of being attentive to symptoms and knowing which interventions are best to
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treat all symptoms. In the case of alcohol withdrawal, the intervention is the use of a
benzodiazepine to reduce all symptoms associated with withdrawal. Reducing symptoms
may in turn reduce addictive effects, potentially improving physical and mental states.
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Method
Purpose
The purpose of this project is to conduct a systematic review to determine if the
use of symptom-triggered dosing compared to fixed-schedule dosing of benzodiazepines
for the treatment of AWS decreases total dosage of benzodiazepines administered. The
research question is: Does the use of symptom-triggered therapy for alcohol withdrawal
decrease total dosage of benzodiazepines given compared to fixed-dosed scheduling
therapy?
Inclusion and Exclusion Criteria
Inclusion criteria included inpatients, outpatients, and adults aged 18 and over,
full-text articles, English language, RCTs, and studies that compared fixed and symptombased benzodiazepine therapy. Exclusion criteria included pediatric focused articles
(younger than 18 years old) and those involving participants with mental illness. The
dates of the studies ranged from 2011-2019.
Search Strategy
This systematic review was conducted using the databases CINAHL, Google
Scholar, and Cochrane. The search terms used included alcohol withdrawal, alcohol
abuse treatment, symptom-triggered therapy, and fixed-dosed therapy. The articles were
chosen based on the abstracts and the inclusion and exclusion criteria.
The Preferred Reporting Items for Systematic Reviews and Meta-analyses
(PRIMSA) was used for evaluating information of each RCT in this systematic review.
The Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) is
an evidence-based minimum set of items for reporting in systematic reviews and meta-
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analyses (Moher et al., 2009). This method focuses on reporting the findings from
multiple randomized controlled trials (RCTs) and other types of research (Moher et al.,
2009). The PRISMA method can evaluate the interventions outlined in certain research
papers (Moher et al., 2009). A systematic review is a review of a research question by
finding relevant literature and collecting and analyzing the data from that literature
(Moher et al., 2009). The PRISMA method consists of a 27-item checklist and a fourphase flow diaphragm. The flow diagram is illustrated in Appendix A and shows the flow
of information through different stages of a systematic review. With the diagram, you can
map out the number of articles identified, included and excluded, and the reasons for
exclusions (Moher et al., 2009). The PRISMA checklist illustrated in Appendix B allows
review of areas in accordance with a systematic review, which include title, abstract,
methods, results, discussion, and findings (Moher et al., 2009).
Data Collection and Synthesis
The author reviewed a total of 10 papers and excluded 6 because they were not
randomized controlled trials. Some of the articles also were not within a time frame of ten
years as search criteria of 2010-2020 were the range used. The articles chosen ranged
from 2011-2019. All studies also excluded patients with severe mental illness.
This author carefully reviewed the chosen RCTs, and pertinent information was
extracted and organized into tables. Table 1 includes the purpose, setting, sample, and
design method of the articles. Table 2 will include the withdrawal scale used, medications
used, exclusion criteria, and any limitations of the studies.
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Table 1.
Purpose

Setting and Time
Frame

Sample

Design Method

Citation

-To compare 24hour symptom
triggered therapy
and fixed-schedule
therapy

Addiction ward at a
psychiatric tertiary
teaching hospital

Randomized
control study

-7 days

80 patients on
the addiction
ward at PSH
Institute of
Medical Science
and Research, a
tertiary teaching
medical college
hospital

Gopal, R., &
Chennatte, S. S.
(2019).
Comparing 24hour symptom
triggered therapy
and fixed
schedule
treatment for
alcohol
withdrawal
symptoms-A
randomized
control
study. Asian
Journal of
Psychiatry, 48,
101888-101888.

-Compare efficacy
of a benzodiazepine
loading versus a
symptom triggered
protocol in the
management of
alcohol withdrawal

Stanford University
Medical Center and
Palo Alto Veterans
Affairs

47 patients
admitted to one
of two tertiary
medical centers

Prospective,
randomized
controlled trial

Maldonado, J. R.,
Nguyen, L. H.,
Schader, E. M., &
Brooks III, J. O.
(2012).
Benzodiazepine
loading versus
symptomtriggered
treatment of
alcohol
withdrawal: a
prospective,
randomized
clinical
trial. General
hospital
psychiatry, 34(6),
611-617.

-12 months

20

Comparing fixed
tapering dose
regimen versus
symptom-triggered
regimen of
lorazepam for
alcohol
detoxification

Department of
Psychiatry and Deaddiction at Post
Graduate Institute
of Medical
Education and
Research, Dr. Ram
Manohar Lohia
Hospital

63 male patients

Prospective,
randomized,
double blind
controlled trial

Sachdeva, A.,
Chandra, M., &
Deshpande, S. N.
(2014). A
comparative
study of fixed
tapering dose
regimen versus
symptomtriggered regimen
of lorazepam for
alcohol
detoxification. Al
cohol and
Alcoholism, 49(3)
, 287-291.

163 patients

Randomized
Controlled Trial

Elholm, B.,
Larsen, K.,
Hornnes, N.,
Zierau, F., &
Becker, U.
(2011). Alcohol
withdrawal
syndrome:
symptomtriggered versus
fixed-schedule
treatment in an
outpatient
setting. Alcohol
and
alcoholism, 46(3),
318-323.

-12 months

Symptom-triggered
versus fixedschedule treatment
in an outpatient
setting

Outpatient clinics
in five Copenhagen
Hospitals
-10 days
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Table 2.
Citation

Gopal et al.
(2019)

Maldonado
et al. (2012)

Sachdeva et
al. (2014)

Withdrawal
Scale Used and
any training
given?
Clinical
Institute
Withdrawal
Scale (CIWA)
-staff were
given didactic
lecture and live
demonstration
on how to
administer
CIWA

Clinical
Institute
Withdrawal
Scale (CIWA)
-training was
given to
medical
students by
their seniors

Clinical
Institute
Withdrawal
Scale (CIWA)
-no teaching
specified in
article

Drugs used for
treatment

Exclusion
Criteria

Limitations

5 patients were
given lorazepam,
1 from the STT
group and 4 from
the FST group, the
rest were given
chlordiazepoxide
- patient was given
20mg
chlordiazepoxide
orally or
lorazepam 1mg
orally if the
patient had liver
dysfunction
-lorazepam and
diazepam
- STT group were
treated with
lorazepam and
patients in the FST
group were treated
with diazepam.
Lorazepam dosage
was converted to
diazepam
equivalents based
on the
equipotency
conversion of 1
mg of lorazepam
to 5 mg of
diazepam.
-lorazepam

Age <16 and
>65
- excluded
patients with
severe mental
illness.

-Not double
blind
-study
participants all
men
chlordiazepoxide
and lorazepam
are tapered
differently

-pregnancy,
history of
dementia, abuse
of depressant
agents, acute
intoxication with
CNS agents,
severe hepatic
dysfunction
(INR >2)
- excluded
patients with
severe mental
illness.

-study was not
blind
-small sample
size

-EKG
abnormalities,
cirrhosis,
abnormal
laboratory data
- excluded
patients with

-small sample
size
-only male
subjects

-46 males and 1
female

22

Elholm et al.
(2011)

Short Alcohol
Withdrawal
Scale (SAWS)
-patients were
taught how to
self-administer
SAWS

severe mental
illness.
-chlordiazepoxide -<18 years old,
- In the FST
patients treated
group, 200mg
for AWS within
chlordiazepoxide
the last week,
was prescribed as history of 3 or
a starting dose for more attempts of
patients scoring
outpatient
>12 on SAWS and detoxification
the dose was
within the last
tapered daily by
month, allergy to
25mg. For patients chlordiazepoxide
scoring <12 on
or known drug
SAWS, the
interaction,
starting dose was
severe
80 mg and it was
psychiatric
tapered daily by
illness, suicidal
10 mg
behavior, severe
cardiac or liver
disease, pregnant
and
breastfeeding
women
- excluded
patients with
severe mental
illness.

-study was
outpatient
-patients scored
themselves using
SAWS

Critical Appraisal Tool
The Critical Appraisal Skills Programme (CASP) was used to critically appraise
each RCT and to evaluate the outcomes and revelations of the RCTs. The Critical
Appraisal Skills Programme (CASP) was developed in Oxford in 1993 by Dr. Amanda
Burls as a formal methodology (Singh, 2013). The CASP includes many checklists, each
with 10-12 questions, for any research study found. For this paper, the 11-question
checklist will be used to appraise the RCTs. The checklists allow readers to critically
appraise and screen out certain areas of a research study (Singh, 2013). The CASP
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checklists also allow a reader to identify the strength and weaknesses of a research article
(Singh, 2013). The CASP checklist for systematic reviews will be used for this paper and
is shown in Appendix D.
The CASP tool for systematic reviews consists of three sections with multiple
questions in each section. Section A reviews whether the results of the study are valid.
Six questions are used to help the author identify whether the results are valid or not.
Section B focuses on the results of the study in general and helps to clearly identify what
each article is concluding. Section C explores whether the results will help locally,
meaning impacting the local population (Singh, 2013). This section focuses on how the
results can be applied to practice (Singh, 2013).
Cross Analysis
All of the studies will be cross analyzed in order to compare the differences and
similarities in the findings. Table 3 below was created to organize the differences and
similarities. The purpose of the table is to be able to compare the differences in total
dosage of benzodiazepines received in the symptom-triggered dosing group versus the
fixed dose schedule dosing group. Table 3 also depicts whether any adverse events in any
of the groups occurred.
Table 3
Authors

Symptom
Triggered Group
Total Mean
Dosage of
Benzodiazepines
Received

Fixed Dosing
Group Total
Mean Dosage of
Benzodiazepines
Received

Duration of
Treatment

Adverse Events

Gopal et al.
(2019)

115mg

210 mg

120 hours in
STT group
and 144 hours
in FST Group

None noted
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Maldonado et
al. (2012)

92.4 mg

103.8 mg

Not assessed

Sachdeva et al.
(2014)

9.5 mg

19.9 mg

146 hours in
FST group
compared to
47.8 hours in
STT group

Elholm et al.
(2011)

725 mg

875 mg

-all patients
treated for ten
days

Two patients in
each group
developed
treatmentrefractory
delirium
tremens.
4 patients in the
FST group had
4 adverse
effects
(delirium,
hallucinations,
insomnia, and
increased
severity of
symptoms)
compared to 6
patients in the
STT group
None noted

Summary of Tables
After reviewing all of the RCTs, it is evident that they all share one common
theme. That theme is that the use of symptom triggered therapy (STT) leads to a
decreased total mean dosage of benzodiazepines administered during treatment for
alcohol withdrawal compared to fixed schedule therapy (FST). No major differences
were noted with adverse effects as only one study spoke about adverse effects noted in
both groups. There were limitations to each study as noted above. Three of the
randomized controlled trials were conducted in inpatient settings, and one was conducted
in an outpatient setting.
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Results
Gopal et al. (2019) conducted a randomized control trial to compare the efficacy
of two treatment strategies for AWS, symptom-triggered therapy (STT) and fixedschedule therapy (FST). The primary outcome of the study was to measure the total dose
of benzodiazepine administered and the duration of detoxification in both treatment
groups. This study took place in the de-addiction ward of PSG Institute of Medical
Science and Research, a tertiary teaching medical college hospital. Study participants
were between the ages of 16 and 65 who were admitted and met the DSM IV criteria for
alcohol dependence. Written consent was obtained from all participants. This study was
approved by the human ethics board of the institution. The patients were randomized
using a computer-generated randomization technique into the two treatment strategy
groups. All of the nurses on the de-addiction ward were trained on the use of the CIWAAr through didactic lecture followed by a live demonstration. The nurses were then
shown a video showing an interview done on two patients while another nurse was
conducting a CIWA-Ar.
In the symptom-triggered treatment group, a nurse on the ward performed a
CIWA-Ar on the patients every hour and if the score was found to be below ten for three
consecutive ratings, then the CIWA-Ar was performed every four hours. If the CIWA-Ar
score was greater than or equal to ten, the patient was given 20 mg of chlordiazepoxide
orally or lorazepam 1mg orally if the patient had liver dysfunction (Gopal et al., 2019). In
the fixed-schedule treatment group, when the patient was admitted to the de-addiction
ward, the admitting physician decided the initial dose of benzodiazepine, lorazepam or
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chlordiazepoxide. Starting on the third day of admission, the dose of benzodiazepine
would begin to be tapered daily.
During the course of treatment, an independent investigator who was blind to the
treatment regimens administered CIWAs to patients in both treatment groups for seven
days. A total of 80 patients were included in the study, 40 randomized into each treatment
group. Eleven patients dropped out of the study because they were discharged before
completion of their detoxification. Lorazepam was used for 5 patients and
chlordiazepoxide was used for the remaining patients. All patients in the FST group
received benzodiazepines while 28 patients (70%) in the STT group received
benzodiazepines. Twelve patients (30%) in the STT group were determined to not need
benzodiazepines based on symptom assessment.
The mean total dose of benzodiazepines administered to patients overall in both
treatment groups was 95 mg lower in the STT group than it was in the FST group. The
total mean dosage amount of benzodiazepine in the STT group was 115 mg and 210 mg
in the FST group. The duration of detoxification was significantly shorter in the STT
group than in the FST group. In the STT group, the duration was 120 hours as compared
to 144 hours in the FST group. According to the independent assessor, the CIWA-Ar
scores were similar in both groups being on the low end of the scale, suggesting that
withdrawal symptoms were well controlled. This finding shows that although the CIWAAr scores were similar, the patients in the FST group were given benzodiazepines when
they did not need them.
According to Gopal et al. (2019), the biggest limitation to the study was it not
being a double-blind study. Another limitation was that the tapering doses for
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chlordiazepoxide (10 mg per day) compared to lorazepam (1 mg per day). No patients
suffered from adverse effects during the study, but there was no structured assessment for
adverse effects, which was another limitation cited.
Maldonado et al. (2012) conducted an open, prospective, randomized clinical trial
over a 12-month period to compare the efficacy of a benzodiazepine fixed-schedule
dosing versus a symptom-triggered therapy in the treatment of AWS. The study was
conducted at two tertiary care medical facilities, Stanford University Medical Center
(SUMC) and the Palo Alto Veterans Affairs (PAVA). Patients who were admitted with
alcohol withdrawal symptoms were included. Eligible patients included those with a
history of alcohol withdrawal or dependence, age 18 or older, and anyone who consumed
alcohol within 24 hours of admission. Exclusion criteria included pregnancy, history of
dementia, reports of active abuse of CNS depressants, acute intoxication with CNSactivating agents, severe hepatic dysfunction, or unwillingness to participate in the study.
A total of 47 participants in the study were randomized into two groups, 23
subjects in the FST group and 24 subjects in the STT group. The CIWA-Ar scales were
administered blindly three times a day by a nurse on the unit. Patients in the STT group
were treated with lorazepam and patients in the FST group were treated with diazepam.
Lorazepam dosage was converted to diazepam equivalents based on the equipotency
conversion of 1 mg of lorazepam to 5 mg of diazepam. The total mean dosage of
benzodiazepines administered in the FST group was 103.8 mg and 92.4 mg in the STT
group. Length of stay was not calculated in this study. Two patients in each group
developed treatment-refractory delirium tremens. No patients suffered from respiratory

28

depression or seizures. Per Maldonado et al. (2019), limitations to this study included an
unblinded design and a small sample size.
Sachdeva et al. (2014) also conducted a prospective, randomized, double blind
controlled trial to compare fixed-schedule treatment versus symptom-triggered therapy
for alcohol detoxification. The study took place in at Post Graduate Institute of Medical
Education and Research, a free tertiary care de-addiction center in India. The study
included 63 male participants who were admitted to the de-addiction unit for alcohol
withdrawal. Lorazepam was the only benzodiazepine used in this study for all patients.
The study was conducted between November 2010 and November 2011. All patients
signed consent forms. Exclusion criteria included major Axis-I psychiatric disorders,
severe medical illness (encephalopathy, delirium), dependence on other substances, mini
mental status exam of less than 23, and history of head injury or mental retardation. All
patients were scored using the CIWA-Ar. All patients were randomized into a fixedschedule treatment group or a symptom-triggered treatment group.
The total mean dosage of benzodiazepines in the FST group was 19.9mg
compared to 9.5mg in the STT group. Two patients in the STT group did not receive any
benzodiazepines because they were noted to have mild withdrawal (CIWA-Ar less than
8). All patients in the FST group received benzodiazepines. The duration of treatment in
the FST group was 146 hours compared to 47.8 hours in the STT group. Patients in the
FST group received the drug for 80 hours more than the patients in the STT group.
Patients continued to receive benzodiazepines even after three consecutive CIWA-Ar
scores of less than 8. Four patients in the FST group suffered adverse events compared
with five patients in the STR group. Adverse events were described as seizures, delirium,

29

hallucinations, increased severity of withdrawal symptoms, and insomnia. One patient
had a seizure in the FST group, and no patient had a seizure in the STT group. One
patient in each group developed delirium. No patients suffered from over-sedation.
Limitations to the study includes the decision to include only male subjects.
Another randomized controlled trial was conducted by Elhom et al. (2011) to
investigate whether there are any advantages of treatment of alcohol withdrawal with a
symptom triggered therapy approach versus a fixed-schedule treatment approach. This
study was conducted on an outpatient basis at five Copenhagen hospitals. Exclusion
criteria included patients who had been treated for AWS within the last week, history or
three or more attempts of outpatient detoxification within the last month, allergy to
chlordiazepoxide, severe psychiatric illness, suicidal behavior, severe cardiac or liver
disease, type 1 diabetes, and pregnancy. Informed consent was obtained for all patients.
All patients were treated with chlordiazepoxide. One hundred and fifty-three
patients were included in this study, and they were all randomized into either a FST or an
STT group. In the FST group, 200mg chlordiazepoxide was prescribed as a starting dose
for patients scoring >12 on SAWS, and the dose was tapered daily by 25mg. For patients
scoring <12 on SAWS, the starting dose was 80 mg, and it was tapered daily by 10 mg.
All of the patients in the FST group were told to take the medication in fixed daily doses.
In the STT group, patients scoring >12 on SAWS were prescribed a maximum
daily dose of 300 mg for 10 days. Patients scoring <12 on SAWS were prescribed a
maximum daily dose of 120 mg for 10 days. The patients in the STT group were taught to
administer benzodiazepines to themselves according to their symptoms rated on the
SAWS. Patients in both groups had to personally attend the outpatient clinic daily for 10
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days. The mean dose of chlordiazepoxide in the STT group was 725 mg compared to
875mg in the FST group. Limitations include the fact that this study was done in an
outpatient setting, and that patients had to score themselves using the SAWS and had to
medicate themselves.
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Summary and Conclusions
Alcohol abuse is one of the most common substance abuse disorders in the United
States (Maldonado et al., 2012). It is seen daily in inpatient and outpatient healthcare
settings. A variety of treatment regimens exist for AWS. Within these treatment
regimens, various drugs can be administered, but benzodiazepines are preferred due to
their safety and efficacy (Maldonado et al., 2012). The most commonly used
benzodiazepines are chlordiazepoxide, lorazepam, oxazepam, and diazepam (Maldonado
et al., 2012). The two most commonly used regimens for the treatment of AWS are fixedschedule treatment (FST) and symptom-triggered treatment (STT). The choice of
treatment regimen is generally decided by the provider depending on the severity of the
patient’s withdrawal symptoms based on the first CIWA-Ar completed.
This systematic review was conducted to determine if the use of symptomtriggered dosing compared to fixed-schedule dosing of benzodiazepines for the treatment
of AWS decreases total dosage of benzodiazepines administered during the course of
treatment. A total of four articles were used to conduct this systematic review. The
PRISMA framework was used to guide the selection of articles. CASP was used to
critically appraise each article included. The theoretical framework used was the MiddleRange Theory of Unpleasant Symptoms. Databases used included CINAHL, Google
Scholar, and Cochrane.
After reviewing all four articles, the main finding was that the use of a symptomtriggered dosing regimen for the treatment of AWS led to a decreased dosage of
benzodiazepines administered compared to the fixed-schedule dosing regimen. Although
not specifically stated in the purpose, analysis of these studies also indicated that the use
of symptom-triggered dosing lead to a shorter duration of treatment. No study found that
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the use of symptom-triggered dosing compared to fixed-schedule dosing lead to increased
adverse effects. All studies did note limitations to their studies. Due to the small number
of articles found that were published within the last ten years regarding this subject, it is
clear more research is required. Overall, this systematic review found that the use of
symptom-triggered dosing does in fact decrease the total dosage of benzodiazepines
administered compared to fixed-schedule dosing.
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Recommendations and Implications for Advanced Nursing Practice
The results of this systematic review can be helpful and useful for advanced
practice nurses (APRNs) in all practice settings including outpatient detoxification
centers and inpatient units that admit patients for AWS. The use of a symptom-triggered
dosing strategy can lead to reduction in unnecessary administration of benzodiazepines,
decreased costs, decreased duration of therapy, and decreased use of hospital resources.
Cost is an issue that many facilities face, so the use of this symptom-triggered dosing can
lead to a decreased level of care due to the reduced amount of benzodiazepines
administered requiring close monitoring and assessment. Some of the studies showed that
the use of this regimen led to decreased duration of therapy, which can translate into a
decreased length of stay. Decreased length of stay and duration of therapy also leads to
effective utilization of resources which include drugs, personnel, hospital beds, and time
(Sachdeva et al., 2014).
It is also important to remember that as APRNs, there is a responsibility to
advocate for the patient. When admitting a patient with AWS, many aspects of the
patient’s history and assessment should be taken into consideration, for example the
patients’ blood alcohol level (BAL) and history of withdrawal. For patients with a history
of a more “difficult” withdrawal, they should receive the fixed dosed scheduling regimen
to ensure the patient is receiving consistent benzodiazepines and prevent withdrawal
symptoms. When admitting a patient with who does not have a history of a difficult
withdrawal including intubation and withdrawal seizures, then a symptom triggered
regimen should be considered in efforts to medicate the patient according to their
symptoms and prevent over sedation from over medication to the patient. Advocating to
ensure the patient does not receive over treatment or under treatment for AWS also leads
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to an improved quality of life and better outcomes for the patient. Over sedating a patient
can lead to the patient having a non-existential relationship with the health care team due
to not being able to be part of the plan of care discussions. In contrary, if a patient does
not receive adequate amounts of benzodiazepines, this can lead to adverse outcomes such
as delirium tremens and intensive care unit (ICU) admission. This outcome would lead to
poor family and patient communication, as well as poor communication with the health
care team.
This leads to further discussion stating the need for a protocol development when
caring for and admitting patients with AWS. There must be specific criteria in place in all
health care settings to ensure advanced providers assess their patients adequately and
choose a treatment regimen based on this assessment. Protocols and screening tools must
be developed for universal use among all health care providers in all health care facilities.
Once a protocol is in place, there must be education to ensure all providers including
nursing personnel and advanced providers, are competent using the screening tools and
following the protocols to safely and effectively care for a patient with alcohol
withdrawal symptoms.
Advanced practice nurses everywhere should be aware of this body of research
and their results. APRNs have the responsibility to ensure they provide the best care for
their patients while also practicing in the best interest of their institution. APRNs have an
important role in research and must always be looking for the best treatment options for
their patients. Research efforts need to include any differences in treatment or response
related to race, ethnicity, gender, and sex to assure health equity in treatment. Due to the

35

limitations and limited randomized controlled trials done on this topic, further research
must be done to expand this knowledge base.
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Appendix A

Identification

PRISMA 2009 Flow Diagram

Records identified through
database searching
(n = )

Additional records identified
through other sources
(n = )

Eligibility

Screening

Records after duplicates removed
(n = )

Records screened
(n = )

Records excluded
(n = )

Full-text articles assessed
for eligibility
(n = )

Full-text articles excluded,
with reasons
(n = )

Included

Studies included in
qualitative synthesis
(n = )

Studies included in
quantitative synthesis
(meta-analysis)
(n = )
(PRISMA Transparent Reporting of Systematic Reviews and Meta-Analyses, 2015)
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Appendix B

PRISMA 2009 Checklist
Section/topic

Reported
on page #

#

Checklist item

1

Identify the report as a systematic review, meta-analysis, or both.

2

Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria,
participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and
implications of key findings; systematic review registration number.

Rationale

3

Describe the rationale for the review in the context of what is already known.

Objectives

4

Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons,
outcomes, and study design (PICOS).

Protocol and registration

5

Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide
registration information including registration number.

Eligibility criteria

6

Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered,
language, publication status) used as criteria for eligibility, giving rationale.

Information sources

7

Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify
additional studies) in the search and date last searched.

Search

8

Present full electronic search strategy for at least one database, including any limits used, such that it could be
repeated.

Study selection

9

State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable,
included in the meta-analysis).

TITLE
Title

ABSTRACT
Structured summary

INTRODUCTION

METHODS

Data collection process

10

Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes
for obtaining and confirming data from investigators.

Data items

11

List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and
simplifications made.

Risk of bias in individual
studies

12

Describe methods used for assessing risk of bias of individual studies (including specification of whether this was
done at the study or outcome level), and how this information is to be used in any data synthesis.

Summary measures

13

State the principal summary measures (e.g., risk ratio, difference in means).

Synthesis of results

14

Describe the methods of handling data and combining results of studies, if done, including measures of consistency
2
(e.g., I ) for each meta-analysis.
Page 1 of 2

(PRISMA Transparent Reporting of Systematic Reviews and Meta-Analyses, 2015)
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Appendix C

Lenz, E. R., Pugh, L. C., Milligan, R. A., Gift, A., & Suppe, F. (1997). The middle-range
theory of unpleasant symptoms: an update. Advances in nursing science, 19(3), 14-27.

42

Appendix D
Section A: Are the results of the review valid?
1. Did the review address a clearly focused question?
2. Did the authors look for the right type of papers?
3. Do you think all the important, relevant studies were
included?
4. Did the review’s authors do enough to assess quality
of the included studies?
5. If the results of the review have been combined, was
it reasonable to do so?
Section B: What are the results?
6. What are the overall results of the review?
Comment:
7. How precise are the results?
Comment:
Section C: Will the results help locally?
8. Can the results be applied to the local population?
9. Were all important outcomes considered?
10. Are the benefits worth the harm and the costs?

Yes

No

Can’t Tell

